ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.
Status:
Completed
Trial end date:
2016-10-04
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess, at control visit (V8), the ablative activity of
intravesical administration of Oncofid-P-B on a papillary marker tumor on patients suffering
from multiple primary and recurrent Ta G1-G2 papillary cancer of the bladder after 6 weeks of
weekly study drug administration, through number and percentage of patients with Complete
Response.